Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Capricor Therapeutics Inc (NASDAQ: CAPR) closed the day trading at $6.25 down -3.40% from the previous closing price of $6.47. In other words, the price has decreased by -$3.40 from its previous closing price. On the day, 1.15 million shares were traded. CAPR stock price reached its highest trading level at $6.54 during the session, while it also had its lowest trading level at $6.205.
Ratios:
For a better understanding of CAPR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.37 and its Current Ratio is at 4.37. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Alliance Global Partners on June 30, 2025, initiated with a Buy rating and assigned the stock a target price of $20. On June 26, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $21.
On May 20, 2025, Roth Capital started tracking the stock assigning a Buy rating and target price of $31.Roth Capital initiated its Buy rating on May 20, 2025, with a $31 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 20 ’24 when Nippon Shinyaku Co Ltd bought 2,798,507 shares for $5.36 per share. The transaction valued at 14,999,998 led to the insider holds 7,090,351 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CAPR now has a Market Capitalization of 285731264 and an Enterprise Value of 163974528. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.34 while its Price-to-Book (P/B) ratio in mrq is 2.72. Its current Enterprise Value per Revenue stands at 12.244 whereas that against EBITDA is -2.284.
Stock Price History:
The Beta on a monthly basis for CAPR is 0.73, which has changed by 0.32978725 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, CAPR has reached a high of $23.40, while it has fallen to a 52-week low of $3.98. The 50-Day Moving Average of the stock is -24.52%, while the 200-Day Moving Average is calculated to be -48.11%.
Shares Statistics:
Over the past 3-months, CAPR traded about 2.53M shares per day on average, while over the past 10 days, CAPR traded about 1412570 shares per day. A total of 45.71M shares are outstanding, with a floating share count of 40.16M. Insiders hold about 12.17% of the company’s shares, while institutions hold 36.30% stake in the company. Shares short for CAPR as of 1755216000 were 11352342 with a Short Ratio of 4.50, compared to 1752537600 on 9801806. Therefore, it implies a Short% of Shares Outstanding of 11352342 and a Short% of Float of 28.249999999999996.
Earnings Estimates
The dynamic stock of Capricor Therapeutics Inc (CAPR) is currently attracting attention from 7.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.53, with high estimates of -$0.28 and low estimates of -$0.61.
Analysts are recommending an EPS of between -$1.85 and -$2.37 for the fiscal current year, implying an average EPS of -$2.14. EPS for the following year is $0.47, with 8.0 analysts recommending between $3.47 and -$2.45.
